22 September 2020 - Utrecht
We are pleased to announce our participation in the EUR 26M Series A financing of Salvia BioElectronics, a promising medical device start-up developing a neuromodulation device for the treatment of chronic migraine. As Salvia’s first venture capital investor, Thuja has supported Salvia throughout its early development phase, creating the basis for the current Series A which includes Inkef, Panakes, SHS, Dolby Family Ventures and BOM. Please find the original press release below.
Chronic migraine, in particular treatment-resistant chronic migraine, continues to be a leading cause of disability. Disproportionally affecting women, the disease is closely intertwined with the current opioid crisis. Driven by serial entrepreneurs and supported by top-tier scientific advisors, Salvia aims to provide relief to patients from this disabling disease.
We look forward to seeing Salvia bring its device into the clinic and relief to patients.
Please find the full press release here.